what percentage of overall revenues is Taxotere sales? will the announcement that Taxotere patent has been ruled invalid have much of an effect on SNY's stock price? thank you....anyone in the know? sensible answers only, please.
Its about a $4B per year drug. Some patents expire in Nov 2010 others in 2012, but the erosion is probably in analysts numbers anyway. More of a nasty headline than anything more. Thats why they probably overpay for GENZ which is the bigger risk to the stock in my opinion. Hope this helps.